Cytogen Inc (KQ:217330) — Market Cap & Net Worth
Market Cap & Net Worth: Cytogen Inc (217330)
Cytogen Inc (KQ:217330) has a market capitalization of $62.61 Million (₩92.39 Billion) as of June 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #21090 globally and #1196 in its home market, demonstrating a -0.12% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cytogen Inc's stock price ₩4005.00 by its total outstanding shares 23069547 (23.07 Million). Review 217330 liabilities breakdown to assess the company's total debt and financial obligations.
Cytogen Inc Market Cap History: 2018 to 2026
Cytogen Inc's market capitalization history from 2018 to 2026. Data shows change from $57.32 Million to $62.61 Million (-3.39% CAGR).
Index Memberships
Cytogen Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$270.08 Billion | 0.02% | #542 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$270.08 Billion | 0.02% | #542 of 1384 |
Weight: Cytogen Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cytogen Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cytogen Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Cytogen Inc's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $57.32 Million | $1.23 Billion | -$2.60 Billion | 0.05x | N/A |
| 2019 | $65.40 Million | $798.92 Million | -$4.14 Billion | 0.08x | N/A |
| 2020 | $222.52 Million | $642.67 Million | -$4.89 Billion | 0.35x | N/A |
| 2021 | $318.93 Million | $347.85 Million | -$10.87 Billion | 0.92x | N/A |
| 2022 | $253.27 Million | $760.78 Million | -$18.77 Billion | 0.33x | N/A |
| 2023 | $211.37 Million | $3.18 Billion | -$15.77 Billion | 0.07x | N/A |
| 2024 | $70.90 Million | $10.91 Billion | -$17.12 Billion | 0.01x | N/A |
| 2025 | $140.55 Million | $26.05 Billion | -$12.34 Billion | 0.01x | N/A |
Competitor Companies of 217330 by Market Capitalization
Companies near Cytogen Inc in the global market cap rankings as of June 19, 2026.
Key companies related to Cytogen Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #131 globally with a market cap of $174.56 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $125.14 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #621 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #664 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #131 | Thermo Fisher Scientific Inc | NYSE:TMO | $174.56 Billion | $464.61 |
| #189 | Danaher Corporation | NYSE:DHR | $125.14 Billion | $177.17 |
| #621 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $562.09 |
| #664 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Cytogen Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Cytogen Inc's market cap moved from $57.32 Million to $ 62.61 Million, with a yearly change of -3.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩62.61 Million | -55.45% |
| 2025 | ₩140.55 Million | +98.24% |
| 2024 | ₩70.90 Million | -66.46% |
| 2023 | ₩211.37 Million | -16.54% |
| 2022 | ₩253.27 Million | -20.59% |
| 2021 | ₩318.93 Million | +43.33% |
| 2020 | ₩222.52 Million | +240.24% |
| 2019 | ₩65.40 Million | +14.09% |
| 2018 | ₩57.32 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Cytogen Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $62.61 Million USD |
| MoneyControl | $62.61 Million USD |
| MarketWatch | $62.61 Million USD |
| marketcap.company | $62.61 Million USD |
| Reuters | $62.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cytogen Inc
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained wit… Read more